Navigation Links
NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002
Date:3/23/2011

KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.  Previously, NephRx reported that NX002 had demonstrated significant efficacy when tested in well-validated animal models of oral mucositis.  Mucositis is a debilitating and often dose-limiting condition that affects more than 400,000 cancer patients who receive chemotherapy or radiation therapy in the U.S. each year.  Current treatment options are limited.

"Issuance of this most recent patent further confirms the promising utility of NX002 as a potential treatment for oral mucositis," said James Koziarz, President and CEO of NephRx.  "Mucositis is a painful and debilitating side effect of cancer therapy that can be dose-limiting, jeopardizing patients' chances for successful treatment.  We look forward to advancing the detailed NX002 toxicity studies needed to initiate the mucositis clinical program for NX002."

NX002 is a peptide derived from the naturally occurring growth factor AMP-18, which has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury.  Its multiple biological properties include the ability to protect cells from injury, stimulate cell growth and migration, and increase the accumulation of proteins that bind cells together.  In a study in a well-validated mucositis model, animals treated with NX002 had reduced levels of oral ulceration and a more rapid recovery, with no evidence of toxicity.  NephRx has begun the preclinical toxicology studies of NX002 needed to initiate mucositis clinical trials targeted for late 2011 or early 2012.

The U.S. Patent and Trademark office issued Patent No. 7910543, "Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors."  Rights to this patent, which protects NX002 and related compounds, have been exclusively licensed to NephRx by the University of Chicago.

NX002 may also have applications in acute and chronic diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis.  It has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury. 

About Oral MucositisMucositis is an inflammation and ulceration of the lining of the mouth, throat or gastrointestinal tract associated with cancer chemotherapy and radiation therapy.  The pain resulting from mucositis can be so severe that it is cited by patients as a major reason for discontinuing cancer treatment.  In severe cases, mucositis prevents eating and often results in hospitalization.  Mucositis afflicts approximately 15-40% of patients receiving standard-dose chemotherapy and 76-100% of patients receiving chemotherapy for bone marrow transplant.  It affects virtually all patients receiving radiation therapy for head and neck and gastrointestinal cancers.  In total, an estimated 400,000 patients are affected by mucositis each year in the U.S. alone, and the incidence is rising as use of radiation and chemotherapy increases. About NephRxNephRx Corporation is a clinical-stage biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders, and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis.  NX001 is currently in Phase I testing and will be developed initially for the treatment of delayed graft function in kidney transplant patients.  NX002 is in preclinical development as a treatment for oral mucositis, a common, painful and dose-limiting side effect of cancer chemotherapy and radiation therapy.  For more information, visit http://www.nephrx.com.Contacts:Corporate:Media:NephRx Corp.

GendeLLindheim BioCom PartnersPhilip A. Long

Barbara Lindheim(269) 838-4785

(212) 918-4650
'/>"/>

SOURCE NephRx Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
2. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
3. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
6. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
9. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... 22, 2017 , ... MEDIA OPPORTUNITY: , Save Our Hospital - Albert Lea ... they are rallying against Mayo Clinic. Specifically, media can talk to steering committee members ... decision to close the Albert Lea hospital. , The rally aims to protect the ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... financial setbacks, a senior finds a new lease on life with assistance from ... of people resolve their problem with unsecured debt. The senior is one of ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed with a Curse: ... tithe, and the freedom experienced when breaking free from this misconception. “Cursed with ... M. Harrison. , Published by Christian Faith Publishing, Lysa M. Harrison’s new book ...
(Date:9/22/2017)... ... 22, 2017 , ... “Fruit of the Spirit: “Love””: a delightful adventure ... has created. “Fruit of the Spirit: “Love”” is the creation of published author, Halimah ... mother of five. Halimah is an avid writer, her inspiration for “Fruit of the ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from Pixel ... to do. Users can select from up to two layers of subject matter along ... a mouse all within Final Cut Pro X. , With ProSlideshow Portrait ...
Breaking Medicine News(10 mins):